Rosu40 mg

Rosu 40 mg is a third-generation statin (HMG-CoA reductase inhibitor) prescribed primarily to manage abnormal blood lipid levels and to lower the long-term risk of cardiovascular events. It is used as an adjunct to a cholesterol-lowering diet and lifestyle changes, not as a replacement for them.

Rosu 40 mg is indicated for:

• Primary hyperlipidemia and mixed dyslipidemia — to reduce elevated total cholesterol, LDL-C, Apolipoprotein B (ApoB), non-HDL-C, and triglyceride levels, and to raise HDL-C ("good" cholesterol).
• Hypertriglyceridemia — as an adjunct to dietary therapy to lower elevated triglyceride levels.
• Primary dysbetalipoproteinemia (Type III hyperlipoproteinemia) — as an adjunct to diet.
• Homozygous familial hypercholesterolemia (HoFH) — to reduce LDL-C, total cholesterol, and ApoB in this genetic, treatment-resistant form of high cholesterol.
• Slowing the progression of atherosclerosis — as part of a broader treatment strategy to lower total cholesterol and LDL-C.
• Heterozygous familial hypercholesterolemia (HeFH) in pediatric patients aged 10–17 years — to reduce elevated total-C, LDL-C, and ApoB after an adequate trial of diet therapy has failed.
• Primary prevention of cardiovascular events — risk reduction of myocardial infarction (heart attack), stroke, and arterial revascularization procedures in patients without established coronary heart disease who have multiple risk factors.

Rosu 40 mg is considered one of the more potent statins available, achieving significant LDL-C reduction even at relatively low doses compared with older statins such as simvastatin or pravastatin.

Other Anti-anginal & Anti-ischaemic drugs, Statins

Mechanism of Action

Rosu 40 mg is a selective and competitive inhibitor of HMG-CoA reductase, the rate-limiting enzyme that converts 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) into mevalonate, an essential precursor in the cholesterol biosynthesis pathway. By blocking this step, Rosu 40 mg produces its lipid-modifying effects through two complementary mechanisms:

• It increases the number of hepatic LDL receptors on the surface of liver cells, enhancing the uptake and clearance of LDL cholesterol from the bloodstream.
• It inhibits hepatic synthesis of very-low-density lipoprotein (VLDL), reducing the total number of circulating VLDL and LDL particles.

Rosu 40 mg has high hydrophilicity and minimal penetration into non-hepatic tissue, which contributes to its hepatoselective action and relatively favorable muscle-related side-effect profile compared with some lipophilic statins.

Pharmacokinetics

• Absorption: Peak plasma concentrations are reached approximately 3–5 hours after oral dosing. Absolute bioavailability is approximately 20%, owing to first-pass hepatic uptake and incomplete intestinal absorption.
• Distribution: Approximately 90% of circulating Rosu 40 mg is bound to plasma proteins, mainly albumin. The drug is selectively taken up by the liver, its primary site of action.
• Metabolism: Rosu 40 mg undergoes limited hepatic metabolism (roughly 10%), mainly via the CYP2C9 enzyme, with minor involvement of CYP2C19. This low dependence on cytochrome P450 metabolism means Rosu 40 mg has fewer clinically significant CYP-mediated drug interactions than statins such as simvastatin or atorvastatin, which rely heavily on CYP3A4.
• Elimination: Approximately 90% of an absorbed dose is excreted unchanged in the feces via biliary excretion, with the remainder eliminated in urine. The elimination half-life is approximately 19 hours, notably longer than most other statins, which allows for flexible once-daily dosing at any time of day.
• Active transport: Hepatic uptake of Rosu 40 mg is mediated in part by the OATP1B1 transporter; genetic variation in this transporter can influence individual drug exposure and myopathy risk.

Chemical Information

Rosu 40 mg Calcium has the molecular formula C22H28FN3O6S (as the calcium salt of the parent compound) and belongs to the synthetic statin subclass, distinguishing it structurally from fermentation-derived statins like lovastatin and simvastatin.

Rosu 40 mg has fewer cytochrome P450-mediated interactions than many other statins, but several clinically important interactions still require dose adjustment or monitoring:

• Cyclosporine: Significantly increases Rosu 40 mg plasma exposure. The Rosu 40 mg dose should be limited to 5 mg once daily.
• Gemfibrozil: Markedly raises Rosu 40 mg blood levels and increases the risk of myopathy. Concurrent use should be avoided; if unavoidable, limit Rosu 40 mg to 10 mg once daily.
• Lopinavir/Ritonavir or Atazanavir/Ritonavir (HIV protease inhibitors): Increase Rosu 40 mg exposure; limit the dose to 10 mg once daily.
• Coumarin anticoagulants (e.g., Warfarin): Combination can prolong the International Normalized Ratio (INR) and increase bleeding risk. INR should be stable before starting Rosu 40 mg and monitored closely during initiation or dose changes.
• Fibrates (Fenofibrate) and Niacin: Concomitant use may increase the risk of skeletal muscle toxicity, including myopathy and rhabdomyolysis.
• Antacids (aluminium and magnesium hydroxide combinations): Can reduce Rosu 40 mg absorption by up to 50% if taken simultaneously. Antacids should be taken at least 2 hours after Rosu 40 mg.
• Colchicine: Rare cases of myopathy and rhabdomyolysis have been reported with combined use; caution and monitoring are advised.
• Oral contraceptives or hormone replacement therapy: Co-administration may modestly increase ethinyl estradiol and norgestrel plasma levels; this should be factored in when prescribing.

Always inform your doctor or pharmacist about all prescription medicines, over-the-counter drugs, and supplements being taken before starting Rosu 40 mg.

Rosu 40 mg is generally well tolerated. Most side effects are mild and resolve on their own, though some require prompt medical attention.

Common Side Effects

• Headache
• Myalgia (muscle aches)
• Asthenia (general weakness or fatigue)
• Constipation
• Abdominal pain
• Nausea
• Dizziness

Less Common Side Effects

• Diarrhea or upset stomach
• Skin rash or itching
• Sleep disturbances
• Mild increase in blood sugar levels

Serious Side Effects (Seek Medical Attention)

• Myopathy and rhabdomyolysis: Unexplained muscle pain, tenderness, or weakness accompanied by fever or dark urine may indicate serious muscle breakdown and requires immediate medical evaluation.
• Liver injury: Symptoms such as yellowing of the skin or eyes, dark urine, unusual fatigue, or upper abdominal pain may signal liver dysfunction.
• Immune-mediated necrotizing myopathy: A rare but recognized autoimmune muscle disease associated with statin use, presenting as proximal muscle weakness and elevated creatine kinase that persists even after stopping the drug.
• Hypersensitivity reactions: Including rash, angioedema, or anaphylaxis in rare cases.
• Peripheral neuropathy: Tingling, numbness, or pain in the hands or feet, reported infrequently.

Patients should report any unusual or persistent symptoms to their doctor promptly rather than discontinuing the medication on their own.

Rosu 40 mg is contraindicated during pregnancy. Cholesterol and cholesterol biosynthesis products are essential for fetal development, and inhibiting HMG-CoA reductase may cause harm to the developing fetus. Rosu 40 mg should only be given to women of childbearing potential when pregnancy is highly unlikely and the patient has been informed of the potential risks.

If a patient becomes pregnant while taking Rosu 40 mg, the medication should be discontinued immediately and the prescribing doctor informed without delay.

It is not definitively known whether Rosu 40 mg passes into human breast milk, but related statin drugs are known to be excreted in breast milk in small amounts. Because of the potential for serious adverse effects in nursing infants, Rosu 40 mg is contraindicated in breastfeeding mothers.

• Myopathy risk factors: Use with caution in patients with predisposing factors for myopathy, including age over 65 years, inadequately treated hypothyroidism, renal impairment, and concurrent use of Fibrates, Niacin, Cyclosporine, Gemfibrozil, Lopinavir/Ritonavir, or Atazanavir/Ritonavir.
• Rhabdomyolysis: Therapy should be discontinued immediately if markedly elevated creatine kinase levels occur, or if myopathy is diagnosed or suspected. Treatment should also be temporarily withheld in patients with acute, serious conditions predisposing to renal failure secondary to rhabdomyolysis, such as sepsis, hypotension, dehydration, major surgery, trauma, severe metabolic or endocrine disorders, or uncontrolled seizures.
• Liver function monitoring: Liver enzyme tests are recommended before starting therapy, at 12 weeks after initiation or any dose increase, and periodically (e.g., every six months) thereafter.
• Renal impairment: Proteinuria and hematuria have been observed at higher doses; dose reduction is required in patients with severe renal impairment.
• Diabetes risk: Statin therapy, including Rosu 40 mg, is associated with a modest increase in fasting blood glucose and HbA1c. Blood sugar should be monitored in patients with diabetes or risk factors for diabetes.
• Interstitial lung disease: Rare cases have been reported with statin use; symptoms include dyspnea, dry cough, fatigue, and weight loss.
• Asian patients: Exhibit higher systemic exposure to Rosu 40 mg; a lower starting dose is recommended.
• Alcohol use: Heavy alcohol consumption increases the risk of liver toxicity and should be avoided or minimized during treatment.

There is no specific antidote for Rosu 40 mg overdose. In the event of suspected overdose, the patient should be managed symptomatically with appropriate supportive care, including monitoring of liver function and creatine kinase levels.

Because Rosu 40 mg is highly bound to plasma proteins, hemodialysis does not significantly enhance its clearance from the body. Patients who have taken an excessive dose should seek immediate medical attention or contact a poison control center.

• Store below 30°C, in a cool, dry place.
• Protect from light and moisture.
• Keep tablets in their original packaging until ready for use.
• Keep out of the reach and sight of children.
• Do not use after the expiry date printed on the package.

• Pediatric patients: Approved for patients 10–17 years of age with heterozygous familial hypercholesterolemia, at doses up to 20 mg/day. Safety and efficacy in children under 10 years have not been established.
• Elderly patients: No specific dose adjustment is required based on age alone, but patients over 65 years have an increased risk of myopathy and should be monitored more closely.
• Renal impairment: Mild to moderate renal impairment does not require dose adjustment. Severe renal impairment (CrCl < 30 mL/min/1.73 m²) not on dialysis requires a reduced starting dose of 5 mg and a maximum of 10 mg once daily.
• Hepatic impairment: Contraindicated in patients with active liver disease. Use with caution and close liver function monitoring in patients with a history of liver disease.
• Asian patients: Show approximately two-fold higher plasma exposure compared with Caucasian patients; therapy should be initiated at 5 mg once daily.